Success Metrics

Clinical Success Rate
78.6%

Based on 11 completed trials

Completion Rate
79%(11/14)
Active Trials
0(0%)
Results Posted
82%(9 trials)
Terminated
3(21%)

Phase Distribution

Ph phase_4
1
7%
Ph phase_3
4
29%
Ph phase_1
2
14%
Ph phase_2
7
50%

Phase Distribution

2

Early Stage

7

Mid Stage

5

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
2(14.3%)
Phase 2Efficacy & side effects
7(50.0%)
Phase 3Large-scale testing
4(28.6%)
Phase 4Post-market surveillance
1(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.6%

11 of 14 finished

Non-Completion Rate

21.4%

3 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(11)
Terminated(3)

Detailed Status

Completed11
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
78.6%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (14.3%)
Phase 27 (50.0%)
Phase 34 (28.6%)
Phase 41 (7.1%)

Trials by Status

completed1179%
terminated321%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_2

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

NCT01437488
completedphase_2

Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma

NCT00068393
terminatedphase_2

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

NCT00074165
completedphase_3

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT03252431
completedphase_2

Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

NCT02698891
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT01437488Phase 2

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

Completed
NCT00068393Phase 2

Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma

Completed
NCT00074165Phase 2

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

Terminated
NCT03252431Phase 3

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Completed
NCT02698891Phase 2

Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

Completed
NCT02467868Phase 3

Efficacy and Safety Study With MYL-1401H and Neulasta

Completed
NCT03511378Phase 4

Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer

Completed
NCT01657331Phase 1

Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)

Completed
NCT03251248Phase 1

Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects

Completed
NCT03559387Phase 2

Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia

Terminated
NCT01692691Phase 2

Dacarbazine and Carmustine in Metastatic Melanoma

Terminated
NCT01516736Phase 3

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Completed
NCT01735175Phase 3

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®

Completed
NCT00261313Phase 2

ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14